Form 4 for DXCM Dexcom

Accepted 2026-02-02 00:00:00 ET · period of report 2026-01-29 · accession 0001093557-26-000011 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
	2026-02-02	2026-01-29	DXCM	Sylvain Jereme M	EVP, Chief Financal Off	A - Grant	$0.00	+7,123	125.9K	+6%	$0
	2026-02-02	2026-01-29	DXCM	Sylvain Jereme M	EVP, Chief Financal Off	F - Tax	$73.36	-2,652	123.2K	-2%	-$194.6K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2026-01-29	A	A	7,123	$0.00	125,859	D	—	—	(F1) Represents shares issued to the Reporting Person upon vesting of performance-based restricted stock units (PSUs) granted to the Reporting Person on March 8, 2023, resulting from achievement of performance conditions under the PSUs.
2	Common	Common Stock	2026-01-29	F	D	2,652	$73.36	123,207	D	—	—	(F2) Represents the number of shares required to be withheld by the Issuer to cover tax withholding and remittance obligations in connection with the net settlement of PSUs and does not represent a sale by the Reporting Person. (F3) Included in this number are 83,328 unvested restricted stock units, 35,906 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 22,798 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 17,368 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 7,256 of which were granted on March 8, 2023 and shall vest through March 8, 2026, and 79 additional shares acquired under the Issuer's Amended and Restated 2015 Employee Stock Purchase Plan.